CXCL8 and renal cell carcinoma: A retrospective analysis of 1344 patients across four phase-3 clinical trials, encompassing patients receiving treatment for melanoma, NSCLC, and renal cell carcinoma found an association between serum CXCL8 levels and poor response to immune checkpoint inhibition [48].